NOTCH1 and non-small cell lung carcinoma: Of particular significance is the isolation of the riboflavin+NOTCH1+ population, which ranged from 0.004% to 2.20%, from the clinical specimens of 13 NSCLC patients, including 8 patients undergoing immunotherapy and chemotherapy (or targeted therapy) and 5 diagnosed (untreated) patients (Fig. 1H and Table S1).